8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Feb 3, 2026·SEC
Kyverna Therapeutics, Inc.(KYTX)Earnings, Financials & Key Ratios
KYTX•NASDAQ
$9.30
$407M mkt cap·Price updated May 7, 2026
AboutKyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Show more
- Revenue$0
- EBITDA-$140M-131.4%
- Net Income-$127M-111.2%
- EPS (Diluted)-3.33-3329900.0%
- ROE-80.74%+35.9%
- ROIC-105.99%+51.2%
- Debt/Equity0.03-83.3%
- Interest Coverage-1004.25-200.9%
KYTX Key Insights
Kyverna Therapeutics, Inc. (KYTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 84 (top 16%)
- ✓Share count reduced 94.3% through buybacks
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KYTX Price & Volume
Kyverna Therapeutics, Inc. (KYTX) stock price & volume — 10-year historical chart
Loading chart...
KYTX Growth Metrics
Kyverna Therapeutics, Inc. (KYTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-91.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-21.17%
Return on Capital
10 Years-71.41%
5 Years-71.41%
3 Years-82.59%
Last Year-87.43%
KYTX Recent Earnings
Kyverna Therapeutics, Inc. (KYTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (56%)
Q2 2026Latest
Mar 26, 2026EPS
$0.80
Est $0.84
+5.3%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.85
Est $0.97
+12.4%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.97
Est $1.00
+3.0%
Revenue
—
Q2 2025
May 13, 2025EPS
$1.03
Est $1.21
+14.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $0.80vs $0.84+5.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.85vs $0.97+12.4% | — |
| Q3 2025 | Aug 12, 2025 | $0.97vs $1.00+3.0% | — |
| Q2 2025 | May 13, 2025 | $1.03vs $1.21+14.9% | — |
Based on last 12 quarters of dataView full earnings history →
KYTX Peer Comparison
Kyverna Therapeutics, Inc. (KYTX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CABA | 409.05M | 4.00 | -2.44 | -121.73% | 0.24 | |||
 AUTL | 409.53M | 1.61 | -1.84 | 496% | -439.68% | -84.69% | 0.12 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 LEGN | 5.28B | 28.57 | -8.87 | 64.47% | -28.83% | -29.22% | 0.41 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 |
Compare KYTX vs Peers
Kyverna Therapeutics, Inc. (KYTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KYTX Income Statement
Kyverna Therapeutics, Inc. (KYTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Sales/Revenue | 5.66M | 7.03M | 0 | 0 | 0 |
| Revenue Growth % | - | 24.2% | -100% | - | - |
| Cost of Goods Sold | 0 | 0 | 1.71M | 2.13M | 1.99M |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 5.66M▲ 0% | 7.03M▲ 24.2% | -1.71M▼ 124.3% | -2.13M▼ 25.0% | -1.99M▲ 0% |
| Gross Margin % | 100% | 100% | - | - | - |
| Gross Profit Growth % | - | 24.2% | -124.3% | -24.96% | - |
| Operating Expenses | 32M | 36.41M | 60.7M | 140.47M | 169.59M |
| OpEx % of Revenue | 565.81% | 518.28% | - | - | - |
| Selling, General & Admin | 6.15M | 8.01M | 12.48M | 30.13M | 34.4M |
| SG&A % of Revenue | 108.73% | 113.98% | - | - | - |
| Research & Development | 25.85M | 28.4M | 48.22M | 112.47M | 136.21M |
| R&D % of Revenue | 457.07% | 404.3% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -2.13M | -1.02M |
| Operating Income | -26.35M▲ 0% | -29.38M▼ 11.5% | -62.41M▼ 112.4% | -142.6M▼ 128.5% | -171.59M▲ 0% |
| Operating Margin % | -465.81% | -418.28% | - | - | - |
| Operating Income Growth % | - | -11.53% | -112.38% | -128.51% | - |
| EBITDA | -25.76M | -28.33M | -60.7M | -140.47M | -169.59M |
| EBITDA Margin % | -455.45% | -403.32% | - | - | - |
| EBITDA Growth % | - | -9.99% | -114.23% | -131.42% | -83.28% |
| D&A (Non-Cash Add-back) | 586K | 1.05M | 1.71M | 2.13M | 1.99M |
| EBIT | -26.35M | -28.83M | -60.18M | -127.33M | -160.92M |
| Net Interest Income | -2K | 500K | 2.1M | 15.22M | 10.69M |
| Interest Income | 1K | 565K | 2.28M | 15.36M | 10.76M |
| Interest Expense | 3K | 65K | 187K | 142K | 73K |
| Other Income/Expense | -4K | 491K | 2.04M | 15.13M | 10.59M |
| Pretax Income | -26.35M▲ 0% | -28.89M▼ 9.7% | -60.37M▼ 108.9% | -127.48M▼ 111.2% | -160.99M▲ 0% |
| Pretax Margin % | -465.88% | -411.29% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -26.35M▲ 0% | -28.89M▼ 9.7% | -60.37M▼ 108.9% | -127.48M▼ 111.2% | -160.99M▲ 0% |
| Net Margin % | -465.88% | -411.29% | - | - | - |
| Net Income Growth % | - | -9.65% | -108.93% | -111.17% | -91.68% |
| Net Income (Continuing) | -26.35M | -28.89M | -60.37M | -127.48M | -160.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.02▲ 0% | -1.12▼ 9.8% | -0.00▲ 100.0% | -3.33▼ 3329900.0% | -3.71▲ 0% |
| EPS Growth % | - | -9.8% | 99.99% | - | -21.17% |
| EPS (Basic) | -1.02 | -1.12 | -0.00 | -3.33 | - |
| Diluted Shares Outstanding | 25.8M | 25.8M | 673.62M | 38.33M | 43.42M |
| Basic Shares Outstanding | 25.8M | 25.8M | 673.62M | 38.33M | 43.42M |
| Dividend Payout Ratio | - | - | - | - | - |
KYTX Balance Sheet
Kyverna Therapeutics, Inc. (KYTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Total Current Assets | 77.09M | 53.25M | 60.66M | 290.6M | 174.93M |
| Cash & Short-Term Investments | 76.07M | 51.32M | 57.54M | 285.98M | 171.14M |
| Cash Only | 76.07M | 37.73M | 34.65M | 96.62M | 34.16M |
| Short-Term Investments | 0 | 13.59M | 22.9M | 189.36M | 136.97M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 1.02M | 0 | 3.12M | 4.62M | 3.79M |
| Total Non-Current Assets | 8.4M | 13.67M | 14.53M | 15.92M | 12.23M |
| Property, Plant & Equipment | 7.81M | 12.44M | 10.61M | 10.66M | 6.32M |
| Fixed Asset Turnover | 0.72x | 0.56x | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 551K |
| Other Non-Current Assets | 593K | 1.23M | 3.92M | 5.26M | 19.43M |
| Total Assets | 85.49M▲ 0% | 66.92M▼ 21.7% | 75.19M▲ 12.4% | 304.64M▲ 305.1% | 187.16M▲ 0% |
| Asset Turnover | 0.07x | 0.10x | - | - | 0.00x |
| Asset Growth % | - | -21.72% | 12.36% | 305.14% | 189.53% |
| Total Current Liabilities | 15.93M | 11.95M | 19.86M | 33.76M | 33.87M |
| Accounts Payable | 773K | 1.45M | 4.36M | 4.62M | 3.02M |
| Days Payables Outstanding | - | - | 931.85 | 791.26 | 1.19K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 3.69M |
| Deferred Revenue (Current) | 6M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.72M | 565K | 9.77M | 4.88M | 20.21M |
| Current Ratio | 4.84x | 4.45x | 3.05x | 8.61x | 8.61x |
| Quick Ratio | 4.84x | 4.45x | 3.05x | 8.61x | 8.61x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 115.81M | 8.29M | 6.16M | 4.3M | 1.34M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 4.74M | 8.29M | 6.16M | 4.3M | 11.34M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 110.05M | 6K | 0 | 0 | 0 |
| Total Liabilities | 131.74M | 20.25M | 26.02M | 38.06M | 35.21M |
| Total Debt | 5.55M | 10.56M | 9.08M | 8.24M | 5.02M |
| Net Debt | -70.51M | -27.17M | -25.57M | -88.38M | -29.14M |
| Debt / Equity | - | 0.23x | 0.18x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | 0.17x |
| Interest Coverage | -8782.00x | -452.06x | -333.72x | -1004.25x | -2204.37x |
| Total Equity | -46.25M▲ 0% | 46.68M▲ 200.9% | 49.18M▲ 5.4% | 266.59M▲ 442.1% | 151.95M▲ 0% |
| Equity Growth % | - | 200.91% | 5.36% | 442.1% | 309.63% |
| Book Value per Share | -1.79 | 1.81 | 0.07 | 6.95 | 3.50 |
| Total Shareholders' Equity | -46.25M | 46.68M | 49.18M | 266.59M | 151.95M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -46.78M | -75.68M | -136.04M | -263.52M | -387.02M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -26K | 4K | 105K | 29K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
KYTX Cash Flow Statement
Kyverna Therapeutics, Inc. (KYTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Cash from Operations | -22.16M | -36.11M | -52.41M | -114.25M | -114.25M |
| Operating CF Margin % | -391.71% | -514.06% | - | - | - |
| Operating CF Growth % | - | -63% | -45.13% | -117.99% | -265.37% |
| Net Income | -26.35M | -28.89M | -60.37M | -127.48M | -160.99M |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.99M |
| Stock-Based Compensation | 7.25M | 929K | 2.22M | 8.36M | 4.68M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 850K | 1.13M | 605K | -5.12M | -151K |
| Working Capital Changes | -4.49M | -10.33M | 3.42M | 7.86M | -2.78M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 11K | 677K | 4.08M | 736K | -6.91M |
| Cash from Investing | -1.29M | -14.1M | -8.79M | -160.9M | 86.52M |
| Capital Expenditures | -1.29M | -768K | -621K | -2.21M | -928K |
| CapEx % of Revenue | 22.79% | 10.93% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 70K |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 7.66M | 1.91M |
| Cash from Financing | 72.52M | 11.88M | 58.12M | 337.11M | 210K |
| Debt Issued (Net) | -41K | -249K | -781K | -956K | -970K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 623K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 30K | 175K | -1M | -3.1M | -94K |
| Net Change in Cash | 49.08M▲ 0% | -38.33M▼ 178.1% | -3.08M▲ 92.0% | 61.96M▲ 2113.7% | -70.5M▲ 0% |
| Free Cash Flow | -23.44M▲ 0% | -36.88M▼ 57.3% | -53.03M▼ 43.8% | -116.45M▼ 119.6% | -158.37M▲ 0% |
| FCF Margin % | -414.5% | -525% | - | - | - |
| FCF Growth % | - | -57.32% | -43.79% | -119.6% | -62% |
| FCF per Share | -0.91 | -1.43 | -0.08 | -3.04 | -3.04 |
| FCF Conversion (FCF/Net Income) | 0.84x | 1.25x | 0.87x | 0.90x | 0.98x |
| Interest Paid | 3K | 65K | 187K | 0 | 18K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
KYTX Key Ratios
Kyverna Therapeutics, Inc. (KYTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | -13660.99% | -125.95% | -80.74% | -105.95% |
| Return on Invested Capital (ROIC) | - | -217.11% | -105.99% | -105.99% |
| Gross Margin | 100% | - | - | - |
| Net Margin | -411.29% | - | - | - |
| Debt / Equity | 0.23x | 0.18x | 0.03x | 0.03x |
| Interest Coverage | -452.06x | -333.72x | -1004.25x | -2204.37x |
| FCF Conversion | 1.25x | 0.87x | 0.90x | 0.98x |
| Revenue Growth | 24.2% | -100% | - | - |
KYTX SEC Filings & Documents
Kyverna Therapeutics, Inc. (KYTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
KYTX Frequently Asked Questions
Kyverna Therapeutics, Inc. (KYTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kyverna Therapeutics, Inc. (KYTX) grew revenue by 0.0% over the past year. Growth has been modest.
Kyverna Therapeutics, Inc. (KYTX) reported a net loss of $161.0M for fiscal year 2024.
Dividend & Returns
Kyverna Therapeutics, Inc. (KYTX) has a return on equity (ROE) of -80.7%. Negative ROE indicates the company is unprofitable.
Kyverna Therapeutics, Inc. (KYTX) had negative free cash flow of $158.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More KYTX
Kyverna Therapeutics, Inc. (KYTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates